Loading...

PODCAST

Beyond Biotech - the podcast from Labiotech

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what"s happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.

news tech news

All Episodes

34:23

Saudi Arabia's biotech momentum: inside RGMBS 2026

Beyond Biotech - the podcast from Labiotech ·

2026/10/09

Saudi Arabia has spent the last four years building one of the most ambitious biotech gatherings in the region: the Riyadh Global Medical Biotechnology Summit. This September, the fourth edition brought together delegations from more than 57 countries and over 200 speakers, closing with more than 40 agreements and initiatives worth over SAR5 billion. From gene editing and genomics to AI-driven drug discovery and biomanufacturing, the Summit is positioning itself as a serious node in the globa...

en-us

36:16

How Flagship's Valo is reshaping AI drug discovery...

Beyond Biotech - the podcast from Labiotech ·

2026/10/02

AI has been one of the biggest buzzwords in biotech for years now — but for all the technological progress, actual R&D productivity gains have been hard to find, and the cost of developing a new drug keeps climbing. My guest today believes that's because AI alone was never going to be the answer. Valo, a biotech founded by Flagship Pioneering, is betting on a different approach: combining AI, predictive chemistry, and — crucially — real-world human data from the very start of drug discov...

en-us

44:11

Theialife’s race to bring a childhood myopia...

Beyond Biotech - the podcast from Labiotech ·

2026/09/25

By 2050, nearly half the world's population is expected to be myopic, with around a billion people projected to progress to high myopia — a leading cause of irreversible vision loss later in life. Children face a narrow window in which to intervene, while the eye is still growing, before those structural changes become permanent. Yet despite the scale of the problem, there is still no FDA-approved drug that slows myopia progression in children, a gap underscored just last month when the FDA d...

en-us

40:27

The best biotech conversations you missed this summer

Beyond Biotech - the podcast from Labiotech ·

2026/09/18

Summer is a busy time for everyone, guests and listeners alike, so today we're taking stock. This is our Summer Recap — a clips episode pulling together the best moments from conversations you might have missed over the past few months. We'll hear from Randy Teel of Arvinas and Per Lundin of Evox on two very different ways of getting drugs to the brain, and Laurent Lévy of Nanobiotix on outsmarting the liver altogether. We'll meet the founders behind these companies, including Andy Parker of ...

en-us

30:48

Rewriting the rules of genetic medicine with tRNA...

Beyond Biotech - the podcast from Labiotech ·

2026/09/11

Most genetic medicines are built to treat one gene, one mutation, one disease at a time. That's true even for the newest modalities — gene therapy, gene editing, mRNA — each still has to be engineered disease by disease. Alltrna is testing a different idea: that the real target isn't the gene, but the process of translation itself, where genetic instructions become protein. The company's lead approach focuses on nonsense mutations, a shared error responsible for roughly a tenth of all genetic...

en-us

31:08

How Evox Therapeutics is targeting CNS diseases with...

Beyond Biotech - the podcast from Labiotech ·

2026/09/04

Gene therapy has largely stayed out of the brain, and the blood-brain barrier has been the reason why — it protects the brain from harm, but it also blocks most advanced medicines from ever reaching it. That's now beginning to change. The recent FDA approval of a brain-penetrant enzyme therapy for Hunter syndrome showed that biologics can cross that barrier and work. The next question is whether gene editing can do the same. My guest today is Dr. Per Lundin, Co-Founder and CEO of Evox Therape...

en-us

34:11

BIOSPAIN 2026: partnering, policy, and the rise of...

Beyond Biotech - the podcast from Labiotech ·

2026/08/28

Today we’re thrilled to bring you a special episode highlighting one of Europe’s premier biotechnology events: BIOSPAIN 2026. Joining us is Stuart Medina of Asebio, who will take us inside this landmark gathering. For the first time and in response to strong sector demand and growing interest, BIOSPAIN moves to an annual format. Hosted this year in vibrant Bilbao in Spain’s dynamic Basque Country, the event runs from 29 September to 1 October at the Bilbao Exhibition Centre. In this episode w...

en-us

31:21

Beyond biology: Nanobiotix's physics-first approach...

Beyond Biotech - the podcast from Labiotech ·

2026/08/21

What if the key to beating cancer wasn't a new drug, but a new way of thinking about matter itself? That's the question Laurent Lévy asked when he co-founded Nanobiotix over twenty years ago — and it's a question that is now producing some genuinely compelling answers in the clinic. Nanobiotix is a Paris-based biotech pioneering what they call physics-based nanomedicine. Their lead asset is a radioenhancer made of hafnium oxide nanoparticles, designed to be injected directly into a tumor and ...

en-us

43:01

How Cancer Research Horizons is building the future...

Beyond Biotech - the podcast from Labiotech ·

2026/08/14

Cancer is still the leading cause of death by disease in children and young people — yet in the last twenty years, only a handful of drugs have been approved specifically to treat it. Most paediatric cancer treatments are simply adult drugs, repurposed, often at real long-term cost to the children who survive. Today's guest is working to change that, and much more besides. Tony Hickson is Chief Business Officer for Cancer Research Horizons, Cancer Research UK's innovation engine, respon...

en-us

36:12

Why Western pharma is sleeping on China's circular...

Beyond Biotech - the podcast from Labiotech ·

2026/08/07

RNA therapeutics has had its defining moments. Antisense oligonucleotides. siRNA. And then, of course, mRNA — which went from a niche academic curiosity to the backbone of a global vaccine program in a matter of months. The next chapter may be circular RNA. CircRNA is more stable than linear mRNA, longer-lasting in the body, and potentially re-dosable. And one company has quietly built what may be the most advanced independent circRNA platform in the world — and with barely a single line of ...

en-us

42:03

Gain Therapeutics: a first-in-class,...

Beyond Biotech - the podcast from Labiotech ·

2026/07/31

Today we welcome Gene Mack, President and CEO of Gain Therapeutics. With over 25 years of experience spanning biochemistry, Wall Street analysis, and biotech leadership, Gene brings deep expertise in capital markets, strategy, and drug development. He joined Gain in 2024 and stepped into the CEO role in early 2025. Gain Therapeutics is a clinical-stage biotech pioneering next-generation allosteric small molecule therapies. Using its proprietary Magellan platform, which combines 3D struc...

en-us

40:12

This nonprofit is building the ecosystem to cure...

Beyond Biotech - the podcast from Labiotech ·

2026/07/24

Epidermolysis bullosa, or EB, is one of those diseases that stops you in your tracks the moment you understand it. Skin so fragile that the gentlest touch can cause blisters and open wounds. No cure. And for most of its history, very little serious drug development attention. That's where today's guest comes in. Martin Steiner is Managing Director of DEBRA Research, a non-profit organization with a single-minded mission: to make EB curable. But DEBRA Research isn't a lab. It doesn't run...

en-us

25:16

How BIO-Europe is expanding beyond dealmaking in 2026

Beyond Biotech - the podcast from Labiotech ·

2026/07/17

The life sciences industry has always had one great meeting place, a few days in November where the deals get done, the partnerships form, and the direction of the industry quietly shifts. For more than three decades, that place has been BIO-Europe. But this year, something is changing. BIO-Europe has always been the destination for BD professionals and dealmakers. In 2026, it's expanding — broadening its scope to become what the organisers are calling the epicenter of biotech, with new...

en-us

31:19

Turning cancer cell dependencies into targeted therapies

Beyond Biotech - the podcast from Labiotech ·

2026/07/10

Today I’m delighted to welcome Andy Parker, CEO of Step Pharma. With over 25 years of experience across AstraZeneca, Shire, Zealand Pharma, and venture capital, Andy has led Step Pharma since 2019. The company is pioneering a targeted approach to cancer and blood disorders by inhibiting the enzyme CTPS1. Their lead candidate, dencatistat, blocks this pathway that certain cancer cells and activated immune cells rely on, while sparing healthy cells that use the related CTPS2 enzyme. In this epi...

en-us

35:31

The first PROTAC is here. What comes next in protein...

Beyond Biotech - the podcast from Labiotech ·

2026/07/03

Today I'm sitting down with Randy Teel, Ph.D., President and CEO of Arvinas, a clinical-stage biotech based in New Haven, Connecticut, that is doing something genuinely new in medicine. Arvinas is pioneering a technology called PROTAC protein degradation. It's a platform that doesn't just block disease-causing proteins, but eliminates them entirely using the body's own disposal system to do it. It's a fundamental shift in how we think about drug design, and it's now reached a historic milesto...

en-us

40:32

De-risking neurology drug development with better...

Beyond Biotech - the podcast from Labiotech ·

2026/06/26

Today we welcome Brandy Wilkinson, CEO of GemPharmatech, and Rikki Feng, the company’s Neuroscience Pipeline Leader. Our discussion focuses on a persistent challenge in drug development: neurology’s stubbornly high clinical failure rates. GemPharmatech is tackling this head-on with proprietary models for Alzheimer’s, Parkinson’s, and blood-brain barrier transport that better mirror human disease biology. We explore why mouse models matter more in neurology than in other fields, the desi...

en-us

40:49

BIO International Convention 2026: practical advice...

Beyond Biotech - the podcast from Labiotech ·

2026/06/19

This week we preview the BIO International Convention, starting next week in San Diego. This is the key partnering event of the year where biotechs connect with pharmaceutical companies and investors in partnering meetings, all to advance and fund innovative therapies. My guest is Werner Lanthaler, Founder and CEO of WLAN Holding. Werner spent 15 years as CEO of Evotec SE, scaling the company from 200 employees and €40 million revenue to over 5,000 staff and €800 million. He previously served...

en-us

27:03

Advancing corticosteroids and hormonal therapies for...

Beyond Biotech - the podcast from Labiotech ·

2026/06/12

Today we’re diving into the world of corticosteroids and hormonal therapies — essential APIs that treat everything from asthma and autoimmune diseases to diabetes and endocrine disorders. These molecules may be decades old, but their manufacturing remains highly complex and critical to patients worldwide. Our guest is Olivier Roux, a Senior Director at Curia. He shares how Curia partners with both startups and big pharma to simplify steroid API challenges, solve supply issues, and prepare for...

en-us

43:33

Episode 200 Special: Joachim Eeckhout on building...

Beyond Biotech - the podcast from Labiotech ·

2026/06/05

Welcome to episode 200! Today I’m delighted to welcome back a very special guest: Joachim Eeckhout, the co-founder of Labiotech, co-owner of Knowbio, and founder of The Science Marketer. Joachim tells the Labiotech story, one of vision, persistence, and a deep belief that the European life-sciences sector deserved better storytelling. We go back to the very beginning with someone who was there: the frustrations, a bike tour of France that became legendary, the leap to Berlin, the fundraising ...

en-us

27:30

World MS Day Special: Immunic reveals new hope for...

Beyond Biotech - the podcast from Labiotech ·

2026/05/29

Today we welcome Dr. Daniel Vitt, CEO of Immunic Therapeutics. With World MS Day being tomorrow, the 30th of May, this is the perfect moment to focus on multiple sclerosis — a disease that affects nearly three million people worldwide and still leaves many patients searching for better options. In today’s episode Daniel shares his own journey into biotechnology, walk us through what life with MS really looks like for patients, and explain the science behind Immunic’s most advanced progr...

en-us

218 results

Similar Podcasts

Expres Ráno

Expres FM

朝日新聞AJW 英語ニュース（The Asahi Shimbun Asia & Japan Watch）

朝日新聞ポッドキャスト

Fox News Radio 1 Minute Newscast

FOX News Podcasts

Business of Tech: Daily MSP News & IT Services Analysis

MSP Radio, Dave Sobel, Managed Service...

SBS Greek - SBS Ελληνικά

SBS